News Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™ Continue Reading Previous Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B ProgramNext Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron Related Stories News Trustima Officially Debuts as the Sustainable Global Brand Review Platform News Spain’s Leading Digital Immigration Firm Launches Legal Hub for Remote Workers Seeking the Spain Digital Nomad Visa News Ynvisible Expands into South America Through Strategic Collaboration with ED Technologies News Click Dream Marketing Announces Strategic Transformation from Digital Agency to Membership-Based Education Platform News VIQ Solutions Completes TSXV Listing and Voluntary Delisting from TSX News Silver Hammer Enters into Option Agreement to Acquire 100% Interest in a Strategic and Prospective Silver Project in the Silver Valley of Idaho